EXPLAINER: New drug slows Alzheimer’s but comes with caveats

Jan 6, 2023, 4:14 PM | Updated: Jan 7, 2023, 6:22 am

This Dec. 21, 2022 image provided by Eisai in January 2023, shows vials and packaging for their med...

This Dec. 21, 2022 image provided by Eisai in January 2023, shows vials and packaging for their medication Leqembi. On Friday, Jan. 6, 2023, U.S. health officials approved Leqembi, a new Alzheimer’s drug that modestly slows the brain-robbing disease. The Food and Drug Administration granted the approval Friday for patients in the early stages of Alzheimer's. (Eisai via AP)

(Eisai via AP)

WASHINGTON (AP) — A new Alzheimer’s drug is hitting the market — the first with clear-cut evidence that it can slow, by several months, the mind-robbing disease.

It’s a long-needed new treatment, but experts also are voicing a lot of caution: The drug isn’t a cure, it’s only intended for early-stage patients, requires IV doses every two weeks, and comes with some safety concerns.

It’s not even clear just how noticeable that modest benefit will be in people’s everyday lives.

Still, “it’s a landmark,” said Dr. Richard Hodes, director of the National Institute on Aging. “It’s not enough, but it’s encouraging that there’s something we can do.”

Here are some things to know about the Food and Drug Administration’s approval of lecanemab, to be sold under the brand name Leqembi:


The drug, made by Japan’s Eisai and its U.S. partner Biogen, is designed to target and clear away a sticky protein called beta-amyloid that builds up into brain-clogging plaques — one key hallmark of Alzheimer’s disease.

It targets a slightly different form of that amyloid, possibly explaining why it proved successful in a rigorous study while a long list of prior amyloid-targeting drugs have failed, said Dr. Sam Gandy, an Alzheimer’s expert at New York’s Mount Sinai Hospital.

The FDA cleared a similar drug named Aduhelm in 2021 even though studies never proved it really helped patients, a move that triggered scathing criticism from a congressional investigation.


In Eisai’s 18-month study of nearly 1,800 people, Leqembi appeared to delay early-stage patients from getting worse by about five months.

That was measured on an 18-point scale that tracks cognitive and functional abilities. People who got the drug still worsened but not as rapidly as those given dummy versions — a difference of nearly half a point on that scale by the study’s end.

Experts are divided over how meaningful a benefit that is. It may be hard for families to tell if a loved one’s decline has slowed, Gandy said.

Other experts say slowing the disease early on, when people still function well, is important even if it’s not that easy to spot.

“Several months with better cognition, what’s that worth to you?” Hodes asked. “I think there you can get a strong argument: If I can interact with my family, be independent for months … that’s a very meaningful outcome.”


Like other amyloid-targeting medications, Leqembi can cause brain swelling or small brain bleeds. In Eisai’s study, 13% of drug recipients had swelling and 17% has small brain bleeds.

The likely reason: Amyloid plaques usually form around nerve cells in the brain but sometimes the gunk gets inside blood vessels, too. Pulling amyloid out of those blood vessels can weaken them, making them leaky, Gandy explained.

While the brain swelling and bleeds may cause only minimal symptoms such as dizziness and vision problems, they occasionally can be severe — and several Leqembi users have died while taking the drug, including two who were on blood-thinning medications.

Eisai has said the deaths can’t be attributed to its Alzheimer’s drug. But Gandy said the greatest risk of serious bleeding would be among Leqembi users who also take blood thinners, which are commonly used by older adults to prevent or treat strokes.

Patients also may experience temporary reactions after the infusions that can include fever, flu-like chills, nausea and blood pressure fluctuations.


The drug is only intended for people in the very early stages of Alzheimer’s who also have that tell-tale amyloid buildup.

The FDA warned doctors to use caution if they prescribe Leqembi to people who use blood thinners. Patients also will be urged to get brain scans several times over the course of treatment.

As patients gradually worsen, it’s not clear how long they should continue getting the twice-a-month IV infusions. Study participants are being tracked for longer periods, and other research is exploring even earlier use — before people with amyloid buildup show symptoms.


Eisai says the drug should be available by Jan. 23, but most patients will likely have to wait months to get it.

That’s because health insurers are expected to scrutinize the drug’s effectiveness before deciding whether to cover it, for which patients, and what testing they may require to confirm they are good candidates.

And Medicare, which covers most people with Alzheimer’s, is not expected to pay for the drug until later this year. That’s because the plan for seniors only pays for Alzheimer’s drugs that have received full approval from the FDA — while the agency granted Leqembi’s approval using a shortcut based on preliminary study results. The FDA is set to review that larger 18-month study soon, in anticipation of full approval later this year.


The IV drug will cost about $26,500 for a typical year’s worth of treatment. If insurers cover it, most people won’t pay anywhere near that much — although people with insurance that requires them to shoulder a larger portion of their drug costs could pay thousands a year.


The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.


Image: Scottie Scheffler celebrates after a birdie on the 10th hole during the second round of the ...

Associated Press

No. 1 golfer Scottie Scheffler: From the course to jail and back after Friday arrest

Top-ranked golfer Scottie Scheffler was arrested after police say he dragged an officer while trying to get around a fatal accident Friday.

19 hours ago

Photo: Seattle Times publisher and CEO Frank Blethen announced he will step down at the end of next...

Associated Press

Seattle Times CEO to step down after 4 decades in charge of family-owned paper

Seattle Times publisher and CEO Frank Blethen announced he will step down at the end of next year after four decades of leading the paper.

2 days ago

Image: Andy Jassy, Amazon president and CEO, attends an event on Aug. 15, 2022, in Culver City, Cal...

Associated Press

Comments from Amazon CEO Andy Jassy about unions violated federal law, NLRB judge rules

A federal judge ruled Amazon CEO Andy Jassy violated labor law by making certain anti-union comments during media interviews two years ago.

15 days ago

Image: Former President Donald Trump appears at Manhattan criminal court before his trial in New Yo...

Associated Press

Judge raises threat of jail as he holds Trump in contempt, fines him at trial

Former President Donald Trump was held in contempt of court at his trial Tuesday and fined $9,000 for repeatedly violating a gag order.

18 days ago

Photo: The seal of the Federal Communications Commission (FCC) is seen before an FCC meeting to vot...

David Hamilton, The Associated Press

Net neutrality restored as FCC votes to regulate internet providers

The FCC on Thursday voted to restore "net neutrality" rules that prevent broadband internet providers from favoring some sites over others.

23 days ago

southwest airlines...

David Koenig, The Associated Press

Southwest will limit hiring and drop 4 airports, including Bellingham, after loss

Southwest Airlines will limit hiring and stop flying to four airports as it copes with weak financial results and delays in getting new planes from Boeing.

23 days ago

EXPLAINER: New drug slows Alzheimer’s but comes with caveats